Page 2 - Canale Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference

Praxis Precision Medicines to Present at the Piper Sandler 35th Annual Healthcare Conference
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesPiper sandlerIan stoneCanale communicationsPraxis precision medicines incPrecision medicinesAnnual healthcarePiper sandler healthcare conferencePraxis precision medicinesMedia contact

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies

Praxis Precision Medicines Receives PRIME Designation from the EMA for elsunersen (PRAX-222) for Treatment of SCN2A Gain of Function Developmental Epilepsies
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMarcio souzaIan stoneIonis pharmaceutics incEuropean medical agencyRogcon incPraxis precision medicines incEuropean medicines agencyCanale communicationsFunction developmentalPrecision medicinesPriority medicinesOrphan drug designationRare pediatric disease designationIonis pharmaceuticsPraxis precision medicines

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesSeanp nolanHayleigh collinsElsa rossignolCarolyn hawleyHead of corporate communicationsRegulatory agencyCompany contactTaysha gene therapies incDevelopment expensesDrug administrationExchange commissionData monitoring committeeCanale communicationsEuropean society of gene cell therapySilicon valley bank

Taysha Gene Therapies Reports Third Quarter 2023 Financial

Data from first adult patient in REVEAL Phase 1/2 trial showed TSHA-102 was well-tolerated with no treatment-emergent SAEs as of 20-week assessment with.

United statesCarolyn hawleyElsa rossignolHayleigh collinsSeanp nolanTaysha gene therapies incDevelopment expensesCanale communicationsSilicon valley bankData monitoring committeeCompany contactEuropean society of gene cell therapyDrug administrationRegulatory agencyExchange commissionUt southwestern gene therapy program

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates

Taysha Gene Therapies Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical Updates
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesHayleigh collinsSeanp nolanCarolyn hawleyElsa rossignolCompany contactRegulatory agencyHead of corporate communicationsEuropean society of gene cell therapyCanale communicationsUt southwestern gene therapy programSilicon valley bankTaysha gene therapies incDevelopment expensesData monitoring committeeDrug administration